Updated pediatric hypertriglyceridemia guidance says triglyceride thresholds below 400 mg/dL mainly signal ASCVD risk, while levels above about 885 mg/dL raise pancreatitis risk. Lifestyle changes remain first-line treatment, and pediatric-specific evidence for drug therapy is still limited.
Italian pharmaceutical company Recordati reported 2025 revenues of €2.6 billion and adjusted net profit of €651.1 million, with rare disease therapies driving 29.7% growth. The company projects 2026 core earnings of €995 million to €1.03 billion, anticipating continued momentum in its specialized rare disease treatments.
Anbio Biotechnology shares gained following an upgrade from a sell rating to hold. The company reported $0.04 earnings per share and $2.29 million in quarterly revenue.
| NCT ID | Title | Status | Phase |
|---|---|---|---|
| NCT07727356 |
EndoSense: Continuous Real-Time Monitoring of Health Markers in Endocrine and Metabolic Disorders |
ACTIVE_NOT_RECRUITING | NA |
| NCT07457255 |
Late Endocrine and Metabolic Consequences After Childhood Brain Tumor Treatment |
COMPLETED | NA |
| NCT06326853 |
Neuroendocrine Mechanisms in Adiposity: An Integrated Approach to the Characterization of Potential Pharmacological Novel Targets Based on Experimental and Clinical Models |
NOT_YET_RECRUITING | |
| NCT02162706 |
Salivary Cortisol Measurements by Mass Spectrometry |
COMPLETED |
